Loading...
Loading...
Menu

Rational Exuberance - The Equitile Blog

2nd February 2020

Posted by: Andrew McNally

Silicon versus Pathogens

Within twenty-four hours of the Chinese authorities uploading the genetic code for the Corona virus to the internet, a San Diego based biotech company, Inovio, had digitally designed a vaccine and produced the first samples in its own lab. They started pre-clinical trials within a week and their vaccine, INO-4800, should to be tested on humans (assuming it’s found to be safe) by the early summer. Inovio is not the only company working on a vaccine - they are in healthy competition with, amongst others, Johnson & Johnson, Moderna Therapeutics and scientists in Australia.

It’s a great example of how exponential growth in computing power is leading to a revolution in drug development. During the SARS outbreak in 2003 it took nearly two years before a vaccine was ready for human trials, for the Zika virus of 2015 this was down to six months – this time it will be a matter of weeks.

Digitally designed molecules to fight pathogens might look like the stuff of sci-fi but as processing speeds continue to double every eighteen months, the ability to design and test drugs without ever entering the lab is now normal.

                                                                                 

I’ve been following the development of a US based private company, Schroedinger, which has industrialised molecule design on a grand scale. Whereas traditional approaches to drug discovery might have synthesized 1,000 compounds each year, Schroedinger’s platform can evaluates billions of molecules “in silico” per week with only the most promising molecules reaching the lab – some within the company’s own drug development programs. It’s not possible for us to buy shares in the company but their shareholder base is further testament to the convergence of computing power and bioscience – one of the company’s early investors was no other than Bill Gates.

The connection between processing speeds and drug development is especially clear in genetic science. The cost of sequencing the human genome has fallen from $100,000,000 in 2001 to a little over $1,000 today. It’s no surprise, therefore, that patent filings for gene-based therapies are growing exponentially.     

                                                                                

Whether a vaccine for the Corona virus will be available in time to stop it becoming a pandemic - or more likely before it burns itself out - is yet to be seen. The battle between silicon and pathogens, however, is in full swing.

One can speculate on where this might lead.  Along with ubiquitous computing power, smartphone health monitoring, home testing kits and so on, small companies and individuals can now innovate in a way that was previously the preserve of large corporations. And so, if there are any hobbyists out there who fancy their chances, here are the first 1,020 nucleotides out of 29,904 that make up the RNA of the Wuhan-Hu-Q. Good luck. 

Read more
Categories
Twitter Feed
 
  • RT @MoneyWeek: Why we need to get a grip on our government https://t.co/L7SV8jJA3n https://t.co/2hE4qsPviB

    10 days ago

  • RT @reactionlife: In his historic 1974 speech, Tory intellectual Keith Joseph made this simple insight. In doing so, he fired the starting…

    10 days ago

  • RT @Citywire: In his latest column, @simonevancook explains why economies are like nature and how behavioural science has evolved into a mo…

    205 days ago

  • RT @cfauk: CFA UK welcomes Sylvia Solomon, ASIP as a new member of the CFA UK Board. Sylvia is Director of ESG & Business Development at Eq…

    219 days ago

  • Is inflation back? Twenty charts surveying the evidence on the most crucial investment question of 2021. #investing #inflation #economy

    over a year ago

  • Some thoughts on yesterday's FOMC statement from Equitile's CIO, George Cooper.

    over a year ago

Risk Warning

The value of investments and the income from them can go down as well as up and investors may not get back the amount originally invested and may lose all of their investment. The value of investments in the investment funds contained on this website may be affected by the price of underlying investments. Exchange rate changes may cause the value of overseas investments to rise or fall.

Nothing contained on this website constitutes, and nothing on this website should be construed as, investment advice or a recommendation to buy, sell, hold or otherwise transact in any investment. It is strongly recommended that you seek professional investment advice before making any investment decision.

You should consider whether an investment fits your investment objectives, particular needs and financial situation before making any investment decision. You should also inform yourself and seek advice as to (a) the possible tax consequences, (b) the legal requirements and (c) any foreign exchange restrictions or exchange control requirements which you might encounter under the laws of the countries of your citizenship, residence or domicile and which might be relevant to the subscription, holding, transfer or disposal of interests in any investment fund.

To the extent that this website contains any information regarding the past performance and/or forecast of investment funds, such information is not a reliable indicator of future performance of these investment funds and should not be relied upon as a basis for an investment decision

Equitile Investments Ltd (“Equitile”) offers no guarantee against loss or that investment objectives will be achieved. Please read the Key Investor Information Document, Prospectus and any other offer documents carefully and consult with your own legal, accounting, tax and other advisors in order to independently assess the merits of an investment.

Equitile Investments Ltd is authorised and regulated by the Financial Conduct Authority in the United Kingdom and is a company registered in England, number: 09459099. Registered Office: 2nd Floor, Regis House, 45 King William Street, London EC4R 9AN.

By clicking “Accept” you confirm that you have read and understood the above information.

Accept

Register

Here at Equitile we take your privacy seriously and will only use your personal information to send you monthly fund reports, news and marketing updates regarding Equitile and its funds. If you would like to receive monthly fund reports, news and marketing updates by email please fill out the form below:

Should you no longer wish to hear from us you can let us know at any time and asked to be removed from our database. You can find the details of how we process, store and protect your personal data at http://equitile.com/uploads/equitile-privacy-policy-may-2018.pdf

Register

Thank you for subscribing.